BRENTUXIMAB VEDONTIN FOR SKIN INVOLVEMENT IN REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL

被引：7
|
作者：
Fernandez-Codina, A. [1 ,2 ,3 ]
Nevskaya, T. [1 ]
Pope, J. [1 ]
机构：
[1] Western Univ, Div Rheumatol, Med, London, ON, Canada
[2] Windsor Reg Hosp Ouellette Campus, Med, Windsor, ON, Canada
[3] Hosp Clin Barcelona, Syst Autoimmune Dis, Barcelona, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2115
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0172
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [21] Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase.
    Gordon, Jessica K.
    Davids, Morgana L.
    Doobay, Kamini
    Mersten, Jamie N.
    Magro, Cynthia
    Wildman, Horatio F.
    Lyman, Stephen L.
    Crow, Mary K.
    Spiera, Robert F.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S735 - S735
  • [22] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE PHASE 3 FOCUSSCED TRIAL
    Khanna, D.
    Lin, C. J. F.
    Spotswood, H.
    Siegel, J.
    Furst, D.
    Denton, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 390 - 390
  • [23] A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
    Derk, Chris T.
    Grace, Elizabeth
    Shenin, Max
    Naik, Manisha
    Schulz, Steffan
    Xiong, Wen
    RHEUMATOLOGY, 2009, 48 (12) : 1595 - 1599
  • [24] Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
    Herrick, Ariane L.
    Assassi, Shervin
    Denton, Christopher P.
    NATURE REVIEWS RHEUMATOLOGY, 2022, 18 (05) : 276 - 285
  • [25] Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
    Ariane L. Herrick
    Shervin Assassi
    Christopher P. Denton
    Nature Reviews Rheumatology, 2022, 18 : 276 - 285
  • [26] Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
    Chung, Lorinda
    Silver, Richard M.
    Steen, Virginia
    Furst, Daniel E.
    Castelino, Flavia, V
    Trojanowski, Marcin
    Spiera, Robert
    Domsic, Robyn
    Rodriguez-Pla, Alicia
    Katsumoto, Tamiko R.
    Goulaouic, Helene
    Wang, Hong
    Espinasse, Melanie
    El-Chemaly, Souheil
    Wang, Rui
    RHEUMATOLOGY, 2025,
  • [27] Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
    Diefenbach, Catherine S.
    Hong, Fangxin
    Ambinder, Richard F.
    Cohen, Jonathan B.
    Robertson, Michael J.
    David, Kevin A.
    Advani, Ranjana H.
    Fenske, Timothy S.
    Barta, Stefan K.
    Palmisiano, Neil D.
    Svoboda, Jakob
    Morgan, David S.
    Karmali, Reem
    Sharon, Elad
    Streicher, Howard
    Kahl, Brad S.
    Ansell, Stephen M.
    LANCET HAEMATOLOGY, 2020, 7 (09): : E660 - E670
  • [28] Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
    Fernandez, Anthony
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [29] Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
    Sato, Takeo
    Inokuma, Shigeko
    RHEUMATOLOGY, 2010, 49 (08) : 1607 - 1607
  • [30] Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial
    Kuhn, Annegret
    Haust, Merle
    Ruland, Vincent
    Weber, Ramona
    Verde, Pablo
    Felder, Gerd
    Ohmann, Christian
    Gensch, Kristina
    Ruzicka, Thomas
    RHEUMATOLOGY, 2010, 49 (07) : 1336 - 1345
12345